Relmada Therapeutics Inc ( (RLMD) ) has released its Q4 earnings. Here is a breakdown of the information Relmada Therapeutics Inc presented to its investors.
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for targeted patient populations, particularly in the field of neurosteroid and cancer treatment. The company is advancing its lead investigational program, NDV-01, for high-grade non-muscle invasive bladder cancer, and is preparing to further develop sepranolone for compulsion-related disorders such as Tourette syndrome.
In its latest earnings report, Relmada Therapeutics shared key updates on its financial performance and strategic initiatives for 2024. The company reported a cash balance of $44.8 million as of December 31, 2024, and highlighted its ongoing efforts to transform through strategic product acquisitions, including NDV-01 and sepranolone, which are expected to drive future growth.
Financially, Relmada reported a decrease in both research and development expenses and general and administrative expenses for the fourth quarter and full year 2024 compared to 2023. The net loss for the year was $80 million, an improvement from the previous year’s loss of $98.8 million. The company emphasized its strong financial position with a clean balance sheet, enabling it to support planned operations through key milestones into the first half of 2026.
Looking ahead, Relmada is focused on advancing its clinical programs through key development milestones, including interactions with the FDA and the initiation of new studies. The company remains committed to exploring strategic opportunities to maximize shareholder value while addressing under-served markets with its innovative therapies.